B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) on Tuesday, setting a price target of $63, which is approximately 129.76% above the present share price of $27.42.
Mamtani expects TG Therapeutics to post earnings per share (EPS) of -$0.69 for the third quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in TG Therapeutics, with an average price target of $73.5.
The analysts price targets range from a high of $84 to a low of $63.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $793 thousand and a net profit of -$89.2 million. The company's market cap is $3.88 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.1% and a 47.48% success rate.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.